Individualized IMRT treatment approach for cervical lymph node metastases of unknown primary
In approximately 3-5% of patients presenting with squamous cell cancer (SCC) metastases in cervical lymph nodes, the primary is not found despite extensive clinical evaluation [1, 2] . Treatment of those patients remains controversial lacking evidence from prospective randomized trials. Recommendations include neck dissection and/or radio(chemo)therapy. For more advanced stages, multimodal treatment is recommended. Induction chemotherapy before radio(chemo)therapy followed by surgery depending on response may be an additional option [2, 3, 4] ; however, its value is not proven. The main controversial aspect is the radiotherapy (RT) treatment volume. Planning treatment volumes (PTVs) often include the affected lymph node region as well as contralateral cervical lymph nodes and the mucosal sites of the pharynx in order to cover a putative primary (comprehensive RT) [5] .
Several retrospective single institution studies compared comprehensive conventional radiation to involved field radiation. While some groups demonstrated better local outcome using extended fields [5, 6, 7] , others did not show an advantage for more extensive RT [4, 8, 9, 10] . Furthermore, omitting hypopharyngeal and laryngeal mucosa seems to be feasible as well [1, 11] .
Introduction of intensity-modulated radiotherapy (IMRT) in patients with head and neck cancer showed an improved therapeutic ratio compared to historic conventional three-dimensional techniques [12] . Recently, in the era of IMRT, several study groups used IMRT in patients with cervical lymph node metastases of unknown primary cancer (UPC) and confirmed those good results [13, 14, 15, 16, 17, 18, 19] .
The purpose of this article is to evaluate the outcome of risk-adapted PTVs in patients with cervical lymph node metastases of UPC treated with IMRT.
Material and methods

Patients
From January 2006 to November 2012, 28 consecutive patients presenting with cervical lymph node metastases of UPC were treated in our department with IMRT either postoperatively (n=20) or as definitive treatment (n=8). Diagnosis was proven histologically in all patients showing metastases of SCC. PET-CT was performed routinely before treatment start and was considered for delineation. Patient-and treatment-related parameters are summarized in . Tab. 1. Mean/median follow-up time was 31.6/30.5 months (range 3-78 months). Details regarding surgical neck dissection prior to radiation (n=20) or as postradiation elective neck dissection (END) are listed in . Tab. 2.
Regular follow-up visits were carried out in our joint clinic at the Department of Otorhinolaryngology, Head and Neck Surgery. Institutional standards for patient assessment included physical examination and flexible fiber optic endoscopy approximately every 2 months in the first year of follow-up, every 3 months in the second to third year and every 6 months in the fourth to fifth years.
Treatment
IMRT
Unilateral irradiation was preferred. Based on individual risk factors including clinical, surgical, histopathological, and imaging information, we enlarged treatment fields to the putative mucosal site or the contralateral neck. One crucial risk factor was suspicious enhancement of contralateral lymph nodes or oropharyngeal structures in PET-CT (n=4). In those cases, a biopsy of the questionable region was carried out revealing no malignancy. Nevertheless a certain risk of involvement was supposed in that case-which was the reason to extend PTVs. Other risk factors suggestive for bilateral nodal irradiation were status after pT1 floor of the mouth carcinoma in the past (n=1), recurrent lymph node metastases (n=1), and level I involvement (n=2). "Classical" extensive bilateral treatment was reserved for N2c and bilateral N3 patients (n=5; postoperative: n=1; definitive: n=4). One patient with extensive N3 disease (116 ccm) was only treated unilaterally due to advanced age and poor general condition. Doses and PTVs based on the affected cervical node levels are shown in . Tab. 3.
. Fig. 1, 2 , and . Fig. 3 demonstrate uni-and bilateral RT volumes. We used simultaneously integrated boost (SIB) technique in all patients [20, 21] . SIB-IMRT was performed using the schedules below.
In definitive IMRT patients (n=8): F SIB2.00: 35 fractions with daily SIB doses of 2.00 Gy (PTV1)/1.70 Gy (PTV2) and 1.54 Gy (PTV3) to a total boost dose of 70.00 Gy (five fractions a week). In 1 patient two IMRT series were carried out instead of SIB (50 Gy, 16 Gy boost, single dose: 2.0 Gy, 6 fractions/week). The dose was normalized to the mean dose in PTV1. For intensity optimization, the prescribed dose encompassed at least 95% of the PTV. Additionally, no more than 2% of any PTV received >110% of its prescribed dose, whereas no more than 1% of any PTV received <93% of the prescribed dose.
Target volumes were delineated as follows: the involved lymph nodes included the gross extent of primary disease, taking clinical and radiological findings into account; clinical target volume (CTV) was defined by adding 10-15 mm margin to the gross tumor volume (GTV), another 2-3 mm margin was added from CTV to PTV 1 dependent on proximity to critical structures (e.g., spinal cord or brachial plexus); PTV2 covered areas considered at high risk for potential microscopic disease; and PTV3 included the clinically negative mucosa or lymphatic pathways (elective PTV coverage).
In patients with substantial parts of the pharynx and/or larynx involved in the PTV, 2.0 Gy per session was given. To ensure sufficient dose delivery to the skin close to GTVs, bolus material (0.5-1 cm thickness) was used in patients with skin involvement and/or <5 mm between GTV and the overlying skin.
Irradiation was delivered with five or seven coplanar beam angles by a 6-MV dynamic MLC system (Varian Medical Systems, Palo Alto, CA, USA) using the sliding window technique, or using the volumetric modulated rapid arc technique (VMAT, since April 2010). Patients were immobilized from head to shoulders using a commercially available thermoplastic mask in supine position.
Systemic therapy
Systemic therapy preferably consisted of cisplatin (40 mg/m 2 weekly) and was switched to cetuximab in case of cisplatinrelated adverse effects (cetuximab loading dose: 400 mg/m 2 followed by weekly applications of 250 mg/m 2 [22] ). For patients with contraindications against cisplatin, cetuximab was favored primarily. The indication for systemic therapy was made based on extent of nodal involvement, resection status, extra-nodal extension, age, and Karnofsky performance score. In 2 patients with extended disease (cN3 and cN2c), three cycles of neoadjuvant chemotherapy with TPF (docetaxel 
Surgery
The extent of neck dissection and the number of positive lymph nodes in operated patients is shown in . Tab. 2.
Statistics
Statistical calculation was performed using the statistic program implemented in StatView (Version 4.5; SAS Institute, Cary, NC, USA).
Results
Outcome
Me a n / m e d i a n f o l l o w -u p w a s 31.6/30.5 months (range 3-78 months). The 3-year overall survival rate was 76%. The 3-year mucosal control rate, nodal control rate, and distant metastasisfree survival were 100, 93, and 88%, respectively (. Fig. 4 
Planning treatment volumes
Unilateral SIB-IMRT was performed in 15/28 patients (54%), either postoperatively (n=11) or as definitive treatment (n=4). In 2 of 15 patients unilateral lymph nodes with contralateral mucosa was irradiated (10 to <20 Gy to the contralateral pathways, . Fig. 3 ). 
Systemic therapy
A total of 20 patients received systemic therapy. In 14 of 17 patients receiving chemotherapy, cisplatin had to be stopped after 1 (n=3), 2 (n=2), 3 (n=4), and 4 (n=5) cycles due to rising levels of creatinine (n=6), cytopenia (n=3), reduced general condition (n=4), or tinnitus (n=2). In 6 of the latter a switch to cetuximab was performed. Three patients received cetuximab as first choice due to previously diagnosed chronic renal failure or hearing impairment. Side effects of cetuximab therapy were acneiform skin reaction (grade III, n=3). One patient developed a grade IV allergic reaction.
Treatment tolerance
Early side effects
Grade III acute radiation induced dermatitis was observed in 11 patients (39%). Three patients suffered from cetuximabrelated acneiform skin reaction grade III (11%). One patient reacted with a grade IV anaphylactic shock on loading dose cetuximab and had to be treated on intensive care unit before he fully recovered. One patient developed a grade III glottis edema in the last week of definitive radiotherapy which resolved a few weeks after treatment completion without any invasive therapy (glucosteroids only). This patient had a N3 disease and was only treated unilaterally due to reduced general condition. He died from cranial bleeding 3 months after completion of radiotherapy. During radiochemotherapy, 3 patients had to be hospitalized due to reduced general condition. One patient having received bilateral IMRT received a gastric tube to ensure nutrition. All acute adverse effects were reversible.
Late term effects
No grade II or higher late sequel was seen.
Tab. 3 Simplified description of doses and planning treatment volumes applied, based on lymph node involvement in patients with cervical lymph node metastases of unknown primary cancer treated in our institution with SIB-IMRT Tab. 4 Elective mucosal irradiation. Simplified description (individual adaption due to involved lymph node levels). Examples shown in . Fig. 1 and . Fig. 2 
RT volumes
Discussion
The goal was to evaluate the effectiveness of individualized IMRT target volumes in patients with cervical lymph nodes of UPC.
Planning treatment volumes
Several study groups compared extended treatment fields as described above with volumes confined to the unilateral lymph node side. As some mostly older studies show extensive radiation of bilateral neck and entire mucosal axis to be superior in locoregional control [5, 6, 7] , other studies did not reveal any differences between bilateral and unilateral neck irradiation [8, 9, 10] . In a different approach Barker et al. [11] showed larynx-sparing radiotherapy to result in a high likelihood of locoregional control and survival. Wallace et al. [1] also practicing elimination of larynx and hypopharynx from RT portals showed comparable outcomes in a larger patient collective (n=179). Patel et al. [23] reserved extended RT for patients at higher risk of locoregional failure such as N2-3 status. Studies dealing with different PTVs in UPC patients are summarized in . Tab. 5. Except for sporadic patients being treated with IMRT in those series most of the patients received RT in the pre-IMRT area.
Intensity-modulated radiotherapy
IMRT offers the ability to discriminate between different target volumes, to deliver multiple doses to different targets simultaneously and to reduce the rate and severity of toxicity [15, 19] . Taking those potential 
Individualized IMRT treatment volumes
For every patient in our cohort the RT volume was defined depending on the potential risk of lymph node involvement according to Eisbruch et al. [24, 25] . This approach was adapted to patients with UPC. A summary of our dose and PTV schedule is shown in . Tab. 3 and . Tab. 4. The primary goal was to avoid extensive volumes while treating patients without oncological compromise. Boost dose was delivered to the involved lymph node areas which were usually level II-III/IV. Adjacent unilateral lymph node levels were also included and treated up to 54 Gy or 60-66 Gy, respectively. The rates of mucosal and nodal control and overall survival are comparable with findings in other studies (see . Tab. 5 and . Tab. 6). The 2 patients in our study with persistent disease had large tumor masses of 63 and 116 ccm, respectively. No patient developed a newly diagnosed locoregional failure.
The advantages of IMRT in sparing the parotid glands, pharyngeal tissues, oral mucosa and mandible bone are well documented. In our study, bilateral SIB-IMRT was carried out in 13/28 (46%) patients. In those cases, the mean dose of the contralateral parotid was kept under 20 Gy. Chen et al. [13] observed a median dose of 23.3 Gy to the contralateral parotid gland (compared to 50.5 Gy in conventional 3D treatment). In case of unilateral treatment the contralateral parotid gland only received a median dose of 6.9 Gy in our study which translated to no grade II or higher xerostomia. Another advantage of IMRT in unilateral treatment is the ability to reduce dysphagia while sparing the pharyngeal constrictors. In our series only one patient was in need of a temporary gastric tube.
Chen et al. [14] showed concurrent chemoradiation to be associated with significant more toxicity without a clear advantage to overall survival and locoregional control in UPC patients. Lacking larger randomized trials in patients with UPC, concomitant systemic therapy was generously given as it was shown to be superior in head in neck cancer patients in general especially in presence of certain risk factors like positive resection margins and extra capsular spread [22, 26, 27, 28] . This is supported by Shoushtari et al. [17] who recommend the addition of che- 5, 6 ). We observed no grade II or higher late squeals so far. We tried to establish some factors standing for a higher risk for potential contralateral disease and/or mucosa involvement. Those risk factors are of course not evidenced based and to some extend subjectively motivated by the treating radio-oncologist. Nevertheless, in the lack of randomized trials, this approach seems to be effective in terms of locoregional control so far and should be confirmed in a larger patient cohort with longer follow-up.
Conclusion
Risk-adapted individualized reduction of PTVs is feasible in IMRT treatment of cervical lymph node metastases of UPC showing high mucosal and nodal control rates and a very good treatment tolerance.
